Literature DB >> 28395767

Screening for lung cancer.

Heather F Sateia1, Youngjee Choi2, Rosalyn W Stewart2, Kimberly S Peairs3.   

Abstract

This review will comprise a general overview of the epidemiology of lung cancer, as well as lung cancer risk factors, screening modalities, current guideline recommendations for screening, and our approach to lung cancer screening.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Low-dose chemotherapy; Lung cancer screening

Mesh：

Year:  2017        PMID： 28395767     DOI： 10.1053/j.seminoncol.2017.02.003

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  8 in total

1.  The optimal timing and courses of bevacizumab added to chemotherapy for non-squamous non-small cell lung cancer: revelations from the real-world experience in a single Chinese cancer center.

Authors:  Qianqian Long; Yu Feng; Chang Liu; Xianghua Wu; Huijie Wang; Hui Yu; Xinmin Zhao; Jialei Wang
Journal:  Ann Transl Med       Date:  2020-10

Review 2.  Current clinical trials and patent update on lung cancer: a retrospective review.

Authors:  Harshul Batra; Shrikant Pawar; Dherya Bahl
Journal:  Lung Cancer Manag       Date:  2021-02-15

3.  Prognostic significance and biological function of Lamina-associated polypeptide 2 in non-small-cell lung cancer.

Authors:  Chang Liu; Hui Yu; Xuxia Shen; Jie Qiao; Xianghua Wu; Jianhua Chang; Xunxia Zhu; Jialei Wang; Xiaoyong Shen
Journal:  Onco Targets Ther       Date:  2019-05-16       Impact factor: 4.147

4.  A Tetra-Panel of Serum Circulating miRNAs for the Diagnosis of the Four Most Prevalent Tumor Types.

Authors:  Belén Pastor-Navarro; María García-Flores; Antonio Fernández-Serra; Salvador Blanch-Tormo; Fernando Martínez de Juan; Carmen Martínez-Lapiedra; Fernanda Maia de Alcantara; Juan Carlos Peñalver; José Cervera-Deval; José Rubio-Briones; Jaime García-Rupérez; José Antonio López-Guerrero
Journal:  Int J Mol Sci       Date:  2020-04-16       Impact factor: 5.923

5.  Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center.

Authors:  Chang Liu; Hui Yu; Qianqian Long; Haiquan Chen; Yuan Li; Weixin Zhao; Kuaile Zhao; Zhengfei Zhu; Si Sun; Min Fan; Jianhua Chang; Jialei Wang
Journal:  Front Oncol       Date:  2019-10-22       Impact factor: 6.244

6.  Radiomics Signature to Predict Prognosis in Early-Stage Lung Adenocarcinoma (≤3 cm) Patients with No Lymph Node Metastasis.

Authors:  Li Zhang; Lv Lv; Lin Li; Yan-Mei Wang; Shuang Zhao; Lei Miao; Yan-Ning Gao; Meng Li; Ning Wu
Journal:  Diagnostics (Basel)       Date:  2022-08-06

7.  Tri-Channel Electrochemical Immunobiosensor for Combined Detections of Multiple Exosome Biomarkers of Lung Cancer.

Authors:  Cui Fan; Bingyan Jiang; Wenjia Shi; Dan Chen; Mingyong Zhou
Journal:  Biosensors (Basel)       Date:  2022-06-21

Review 8.  [Research Progress on Lung Cancer Screening].

Authors:  Yazhe Guan; Meng Ren; Dongli Guo; Yutong He
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-08-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.